LOXL2 in epithelial cell plasticity and tumor progression.

Several members of the lysyl oxidase family have recently emerged as important regulators of tumor progression. Among them, LOXL2 has been shown to be involved in tumor progression and metastasis of several tumor types, including breast carcinomas. Secreted LOXL2 participates in the remodeling of the extracellular matrix of the tumor microenvironment, in a similar fashion to prototypical lysyl oxidase. In addition, new intracellular functions of LOXL2 have been described, such as its involvement in the regulation of the epithelial-to-mesenchymal transition, epithelial cell polarity and differentiation mediated by transcriptional repression mechanisms. Importantly, intracellular (perinuclear) expression of LOXL2 is associated with poor prognosis and distant metastasis of specific tumor types, such as larynx squamous cell carcinoma and basal breast carcinomas. These recent findings open new avenues for the therapeutic utility of LOXL2.

[1]  Jie Wu,et al.  Lysyl oxidase G473A polymorphism is associated with increased risk of ovarian cancer. , 2012, Genetic testing and molecular biomarkers.

[2]  Thomas R. Cox,et al.  The rationale for targeting the LOX family in cancer , 2012, Nature Reviews Cancer.

[3]  N. Xia,et al.  Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas , 2012, Medical Oncology.

[4]  Y. Yamaguchi,et al.  A Peptide Derived from Endostatin Ameliorates Organ Fibrosis , 2012, Science Translational Medicine.

[5]  Antonio García de Herreros,et al.  Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. , 2012, Molecular cell.

[6]  M. Nugent,et al.  Recombinant Lysyl Oxidase Propeptide Protein Inhibits Growth and Promotes Apoptosis of Pre-Existing Murine Breast Cancer Xenografts , 2012, PloS one.

[7]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[8]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[9]  M. Perez-Moreno,et al.  Epithelial cell polarity, stem cells and cancer , 2011, Nature Reviews Cancer.

[10]  A. Menssen,et al.  miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions , 2011, Cell cycle.

[11]  J. Lugassy,et al.  The Enzymatic Activity of Lysyl Oxidas-like-2 (LOXL2) Is Not Required for LOXL2-induced Inhibition of Keratinocyte Differentiation* , 2011, The Journal of Biological Chemistry.

[12]  S. Moestrup,et al.  The Conserved Scavenger Receptor Cysteine-Rich Superfamily in Therapy and Diagnosis , 2011, Pharmacological Reviews.

[13]  Christopher A. Maher,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition , 2011, The Journal of cell biology.

[14]  M. Nieto,et al.  The ins and outs of the epithelial to mesenchymal transition in health and disease. , 2011, Annual review of cell and developmental biology.

[15]  S. Germain,et al.  Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. , 2011, Blood.

[16]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation , 2011, Proceedings of the National Academy of Sciences.

[17]  Alberto Martin,et al.  Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas , 2011, EMBO molecular medicine.

[18]  F. Greenaway,et al.  Identification of the copper-binding ligands of lysyl oxidase , 2011, Journal of Neural Transmission.

[19]  Janine T Erler,et al.  The potential for LOXL2 as a target for future cancer treatment. , 2011, Future oncology.

[20]  A. Borczuk,et al.  Lysyl oxidase: A lung adenocarcinoma biomarker of invasion and survival , 2011, Cancer.

[21]  D. Tarin.  Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. , 2011, Seminars in cancer biology.

[22]  Thomas R Cox,et al.  The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. , 2011, Journal of the National Cancer Institute.

[23]  J. Erler,et al.  Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer , 2011, Disease Models & Mechanisms.

[24]  M. Nicolau,et al.  LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. , 2011, Cancer research.

[25]  G. Neufeld,et al.  Receptor activity modifying protein‐3 mediates the protumorigenic activity of lysyl oxidase‐like protein‐2 , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  W. Jiang,et al.  Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer , 2010, Journal of carcinogenesis.

[27]  L. Gerstenfeld,et al.  Lysyl Oxidase-like-2 (LOXL2) Is a Major Isoform in Chondrocytes and Is Critically Required for Differentiation* , 2010, The Journal of Biological Chemistry.

[28]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[29]  C. Wai,et al.  Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.

[30]  Simone Brabletz,et al.  The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? , 2010, EMBO reports.

[31]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[32]  N. Probst-Hensch,et al.  Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC) , 2010, International journal of cancer.

[33]  E. Antecka,et al.  Lysyl oxidase expression and inhibition in uveal melanoma , 2010, Melanoma research.

[34]  U. Beier,et al.  Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review). , 2010, International Journal of Oncology.

[35]  K. Eckardt,et al.  The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia , 2009, The Journal of Biological Chemistry.

[36]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[37]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[38]  Qian Liu,et al.  Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. , 2009, Carcinogenesis.

[39]  S. Roh,et al.  Differential expression of the LOX family genes in human colorectal adenocarcinomas. , 2009, Oncology reports.

[40]  M. Nieto,et al.  Inflammation and EMT: an alliance towards organ fibrosis and cancer progression , 2009, EMBO molecular medicine.

[41]  F. Jónasson.  From epidemiology to lysyl oxidase like one (LOXL1) polymorphisms discovery: phenotyping and genotyping exfoliation syndrome and exfoliation glaucoma in Iceland , 2009, Acta ophthalmologica.

[42]  S. Tajima,et al.  Reciprocal regulation of LOX and LOXL2 expression during cell adhesion and terminal differentiation in epidermal keratinocytes. , 2009, Journal of dermatological science (Amsterdam).

[43]  S. Fong,et al.  Lysyl oxidase‐like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells , 2009, International journal of cancer.

[44]  Robert A. Weinberg,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[45]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[46]  J. Mäki.  Lysyl oxidases in mammalian development and certain pathological conditions. , 2009, Histology and histopathology.

[47]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[48]  J. Erler,et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.

[49]  F. Portillo,et al.  Transcriptional regulation of cell polarity in EMT and cancer , 2008, Oncogene.

[50]  S. Sleijfer,et al.  Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response , 2008, Clinical Cancer Research.

[51]  E. Fearon,et al.  The transcription factor snail represses Crumbs3 expression and disrupts apico-basal polarity complexes , 2008, Oncogene.

[52]  F. Portillo,et al.  Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. , 2008, Cancer research.

[53]  A. Le Bivic,et al.  Polarity complex proteins. , 2008, Biochimica et biophysica acta.

[54]  W. Nelson,et al.  Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. , 2008, Biochimica et biophysica acta.

[55]  G. Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[56]  A. Dimmler,et al.  The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. , 2008, Cancer research.

[57]  K. Csiszȧr,et al.  Active lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin activation and migration in invasive astrocytes , 2007, Neuropathology and applied neurobiology.

[58]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[59]  M. Hendrix,et al.  Paradoxical roles for lysyl oxidases in cancer—A prospect , 2007, Journal of cellular biochemistry.

[60]  S. Fong,et al.  Lysyl oxidase‐like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors , 2007, Genes, chromosomes & cancer.

[61]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[62]  Guojun Wu,et al.  LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. , 2007, Cancer research.

[63]  E. Fuchs,et al.  Catenins: keeping cells from getting their signals crossed. , 2006, Developmental cell.

[64]  H. Kagan,et al.  Lysyl oxidase: an oxidative enzyme and effector of cell function , 2006, Cellular and Molecular Life Sciences CMLS.

[65]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[66]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[67]  K. Csiszȧr,et al.  A molecular role for lysyl oxidase‐like 2 enzyme in Snail regulation and tumor progression , 2005, The EMBO journal.

[68]  Cynthia A. Reinhart-King,et al.  Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.

[69]  Y. Baruch,et al.  Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. , 2005, Journal of hepatology.

[70]  K. Csiszȧr,et al.  Comparative immunocytochemical localization of lysyl oxidase (LOX) and the lysyl oxidase-like (LOXL) proteins: changes in the expression of LOXL during development and growth of mouse tissues , 2004, Journal of Molecular Histology.

[71]  P. Sommer,et al.  The Propeptide Domain of Lysyl Oxidase Induces Phenotypic Reversion of Ras-transformed Cells* , 2004, Journal of Biological Chemistry.

[72]  Jiangang Gao,et al.  Elastic fiber homeostasis requires lysyl oxidase–like 1 protein , 2004, Nature Genetics.

[73]  S. Birge,et al.  Lysyl Oxidase Is Required for Vascular and Diaphragmatic Development in Mice* , 2003, The Journal of Biological Chemistry.

[74]  M. Neeman,et al.  Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. , 2003, Cancer research.

[75]  J. Werner,et al.  Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas. , 2003, Anticancer research.

[76]  Elaine Fuchs,et al.  Sticky Business Orchestrating Cellular Signals at Adherens Junctions , 2003, Cell.

[77]  M. Hendrix,et al.  A molecular role for lysyl oxidase in breast cancer invasion. , 2002, Cancer research.

[78]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[79]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[80]  T. Strassmaier,et al.  Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[81]  G. Martin,et al.  The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[82]  E. Hay.  Organization and fine structure of epithelium and mesenchyme in the developing chick embryo , 1968 .

[83]  B. Davidson,et al.  Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities , 2008, Virchows Archiv.

[84]  L. Dow,et al.  Polarity regulators and the control of epithelial architecture, cell migration, and tumorigenesis. , 2007, International review of cytology.